But tolebrutinib showed something novel at ECTRIMS. In the phase III HERCULES trial, tolebrutinib slowed confirmed disability ...

Sanofi has bolstered the case for its oral BTK inhibitor tolebrutinib as a treatment for multiple sclerosis (MS), due to be filed for approval in the latter half of this year, with new data in a ...

But because we don’t know what’s driving it, we don’t know what to go after.” The study was supported by Sanofi. Cree is a co ...

Sanofi has released phase 3 data from the LUNA 3 trial of rilzabrutinib that should spark some buyer’s delight. | Sanofi has released phase 3 data from the LUNA 3 trial of rilzabrutinib that should ...

Sanofi said the GEMINI 1 and 2 trials of tolebrutinib in relapsing forms of MS are fully enrolled and should read out in time to meet its plan of filing for regulatory approval in the US in 2024.

Q3 2024 Earnings Call Transcript October 25, 2024 Sanofi beats earnings expectations. Reported EPS is $1.57, expectations ...

It's the first anti-CD38 with this data in this setting. Finally, we've shared several positive Phase 3 readouts, including tolebrutinib, one of our BTK inhibitors, which is notable for its effect ...

Tolebrutinib for treating relapsing multiple sclerosis TS ID 11845 Technology appraisal guidance Toripalimab with chemotherapy for treating advanced oesophageal squamous cell cancer without previous ...

Findings showed the study met its primary endpoint demonstrating a reduction in disability accumulation with tolebrutinib compared with placebo. Tolebrutinib was found to delay disability progression ...

Furthest along in the pipeline is tolebrutinib, developed by Paris-based Sanofi to potentially treat SPMS, PPMS and relapsing forms of MS. The investigational agent is an oral central nervous system ...